Deina Hydrocortisone Derivative for Atrophic Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for regenerating atrophic tissues, which are characterized by reduced cell mass, loss of vascularization, and inflammation, particularly in mucosal, cartilage, osteo-articular, vascular, and nervous tissues.
Innovation Solution
The use of Deina, a hydrocortisone derivative with anti-atrophic, anti-inflammatory, and anti-calcificatory properties, stimulates tissue regeneration by restoring physiological conditions and promoting collagen synthesis and vascular regeneration, suitable for both cosmetic and medical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for atrophic tissues, then existing therapeutic options are limited, but effective tissue regeneration is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of hydrocortisone to create Deina, a derivative with enhanced regenerative properties. This structural parameter change transforms the molecule from having primarily anti-inflammatory effects to possessing potent tissue-regenerating capabilities while maintaining anti-atrophic and anti-calcificatory properties, thereby resolving the contradiction between treatment availability and regeneration effectiveness
Solution Approach 2:
The patent converts the harmful effects of atrophy (tissue degradation, inflammation, calcification) into beneficial regeneration processes. Deina is designed to counteract the harmful progression of atrophic conditions by stimulating tissue regeneration, promoting collagen synthesis, and preventing pathological calcification, thereby transforming the pathological state into a regenerative one
2Quantity of substance
If Deina is used to stimulate tissue regeneration, then tissue mass and vascularization are restored, but the complexity of treating multiple tissue types increases
Solution Approach 1:
The patent applies universality by designing Deina as a multi-functional compound that can regenerate multiple tissue types (mucosal, cartilage, osteo-articular connective, vascular, and nervous tissues) through a single agent. This eliminates the need for different treatments for different tissue types, resolving the contradiction between achieving comprehensive tissue restoration and managing treatment complexity
Solution Approach 2:
The patent applies segmentation by addressing different aspects of tissue regeneration (anti-atrophic effects, anti-inflammatory effects, anti-calcificatory effects, collagen synthesis promotion, vascular regeneration) through a single compound with multiple mechanisms of action. This segmented approach to multifunctionality allows Deina to tackle various pathological processes simultaneously without requiring complex combination therapies
3Strength
If Deina promotes collagen synthesis and vascular regeneration, then tissue trophism improves, but the risk of reactive calcification must be controlled
Solution Approach 1:
The patent converts the potential harmful effect of reactive calcification into a beneficial outcome by incorporating anti-calcificatory properties into Deina's mechanism of action. The compound not only promotes tissue regeneration and collagen synthesis but also actively prevents pathological calcification, thereby transforming a potential harm into a protective benefit that enhances overall tissue health
Solution Approach 2:
The patent applies parameter changes by modifying Deina's chemical structure to optimize the balance between pro-regenerative effects and anti-calcificatory effects. The molecular structure is designed to achieve optimal concentrations and ratios of different functional groups that simultaneously promote collagen synthesis and prevent calcification, resolving the contradiction between improving tissue strength and controlling calcification risk
Data Source
AI summary
The invention relates to the hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3, 5-Dihydroxy-3-(2-hydroxy-acetyl)-3a, 6-dimethyl- 7-oxo-dodecahydro-cyclo- penta[alpha]naphthalen-6-yl] -propionic acid, designated as Deina®, for use in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.